Non-Hodgkin lymphoma

[1]  Randy D Gascoyne,et al.  Non-Hodgkin lymphoma , 2016, Medicine.

[2]  R. Advani,et al.  Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update , 2011 .

[3]  W. Wierda,et al.  Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. , 2011, Blood.

[4]  J. Vose,et al.  Peripheral T-cell lymphoma. , 2011, Blood.

[5]  J. Pinilla-Ibarz,et al.  Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. , 2011, Clinical Lymphoma, Myeloma & Leukemia.

[6]  M. Ghielmini,et al.  Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Salles,et al.  Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. , 2010 .

[8]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[9]  A. Hagenbeek,et al.  Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Kimby,et al.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.

[11]  R. Marcus,et al.  Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Horning.  Follicular lymphoma, survival, and rituximab: is it time to declare victory? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Weisenburger,et al.  ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. , 2008, Blood.

[15]  P. Gaulard,et al.  Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. , 2008, Blood.

[16]  T. Robak,et al.  Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Cyster,et al.  Germinal-center organization and cellular dynamics. , 2007, Immunity.

[18]  T. Ittel,et al.  Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Nissen,et al.  A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I‐II non‐hodgkin's lymphomas , 2006, Cancer.

[22]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[23]  David Jung,et al.  Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. , 2006, Annual review of immunology.

[24]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[25]  C. Lynch,et al.  Improved survival of follicular lymphoma patients in the United States. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Gascoyne,et al.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Vose,et al.  Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Gressin,et al.  High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. , 2005, Blood.

[29]  T. Molina,et al.  ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.

[30]  E. Hoster,et al.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  W. Hiddemann,et al.  Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. López-Guillermo,et al.  Follicular lymphoma international prognostic index. , 2004, Blood.

[33]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[34]  J. Byrd,et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[35]  J. Gribben,et al.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Dupont,et al.  Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? , 2001, British journal of haematology.

[37]  M. Tiemann,et al.  Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. , 2001, Blood.

[38]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  B. Cheson,et al.  Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[40]  F. Gherlinzoni,et al.  The role of positron emission tomography (PET) in the management of lymphoma patients. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  J. Coebergh,et al.  The rise in incidence of lymphomas in Europe 1985-1992. , 1999, European journal of cancer.

[42]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  D. Weisenburger,et al.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  L. White,et al.  MR imaging of primary lymphoma of bone: variability of T2-weighted signal intensity. , 1998, AJR. American journal of roentgenology.

[45]  A. Glass,et al.  The national cancer data base report on non‐hodgkin's lymphoma , 1997, Cancer.

[46]  W. Hiddemann,et al.  Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia , 1996, The Lancet.

[47]  D. Weisenburger,et al.  Lymphomatous polyposis. A neoplasm of either follicular mantle or germinal center cell origin. , 1996, The American journal of surgical pathology.

[48]  M. M. Mac Manus,et al.  Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  A. Horwich,et al.  Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[50]  M. Stolte,et al.  Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection , 1995, The Lancet.

[51]  K. Maclennan,et al.  Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. , 1994, British Journal of Cancer.

[52]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[53]  James R. Anderson,et al.  Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  T. Fears,et al.  Non-Hodgkin's lymphoma time trends: United States and international data. , 1992, Cancer research.

[55]  M. Oken,et al.  Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  D. Weisenburger,et al.  The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  D. Weisenburger,et al.  Peripheral T‐cell lymphoma: A clinicopathologic study of 42 cases , 1987, Hematological oncology.

[58]  M. Gospodarowicz,et al.  Patterns of disease in localized extranodal lymphomas. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  T. Miller,et al.  Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  K. Lennert,et al.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.

[61]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[62]  N. Tomita.  [Follicular lymphoma]. , 2014, Nihon rinsho. Japanese journal of clinical medicine.

[63]  G. Fingerle-Rowson,et al.  Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia : a randomised , open-label , phase 3 trial , 2010 .

[64]  W. R. Burack,et al.  The incidence, natural history, biology, and treatment of transformed lymphomas. , 2009, Hematology. American Society of Hematology. Education Program.

[65]  P. Gaulard,et al.  Clinical , biologic , and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d ’ Etude des Lymphomes de l ’ Adulte ( GELA ) trials , 2008 .

[66]  B. Coiffier,et al.  European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  R. Doci,et al.  Staging and Prognostic Factors , 1998 .

[68]  B. Coiffier.  What treatment for elderly patients with aggressive lymphoma? , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  M. Kaminski,et al.  Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. , 1994, Radiology.

[70]  S. Pileri,et al.  Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood. , 1993, Medical and pediatric oncology.

[71]  B. Grosbois,et al.  A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia , 1990 .